[go: up one dir, main page]

FI891226L - Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. - Google Patents

Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. Download PDF

Info

Publication number
FI891226L
FI891226L FI891226A FI891226A FI891226L FI 891226 L FI891226 L FI 891226L FI 891226 A FI891226 A FI 891226A FI 891226 A FI891226 A FI 891226A FI 891226 L FI891226 L FI 891226L
Authority
FI
Finland
Prior art keywords
reseptordeterminanter
autoimmunsjukdom
cell
foer behandling
behandling
Prior art date
Application number
FI891226A
Other languages
English (en)
Other versions
FI891226A7 (fi
FI891226A0 (fi
Inventor
Lawrence Steinman
Scott S Zamvil
Dennis J Mitchell
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22692581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI891226(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of FI891226A0 publication Critical patent/FI891226A0/fi
Publication of FI891226A7 publication Critical patent/FI891226A7/fi
Publication of FI891226L publication Critical patent/FI891226L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI891226A 1988-04-28 1989-03-15 Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. FI891226L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18829788A 1988-04-28 1988-04-28

Publications (3)

Publication Number Publication Date
FI891226A0 FI891226A0 (fi) 1989-03-15
FI891226A7 FI891226A7 (fi) 1989-10-29
FI891226L true FI891226L (fi) 1989-10-29

Family

ID=22692581

Family Applications (1)

Application Number Title Priority Date Filing Date
FI891226A FI891226L (fi) 1988-04-28 1989-03-15 Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.

Country Status (12)

Country Link
EP (1) EP0340109B1 (fi)
JP (2) JPH0272197A (fi)
AT (1) ATE153704T1 (fi)
AU (1) AU635202B2 (fi)
DE (1) DE68928069T2 (fi)
DK (1) DK203489A (fi)
ES (1) ES2104565T3 (fi)
FI (1) FI891226L (fi)
GR (1) GR3024532T3 (fi)
HK (1) HK1005597A1 (fi)
IL (1) IL89865A (fi)
NO (1) NO891705L (fi)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017268A1 (en) * 1990-05-01 1991-11-14 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor variable transcripts as disease related markers
FR2621127B1 (fr) * 1987-09-30 1992-01-31 Roussy Inst Gustave Anticorps monoclonal reconnaissant un epitope de la chaine gamma des recepteurs de surface des cellules t humaines, lignee de cellules d'hybridomes produisant cet anticorps, et utilisation de cet anticorps monoclonal
DE3828582A1 (de) * 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
DE69006018T3 (de) * 1989-03-21 2004-01-15 Immune Response Corp Inc Impfung und methoden gegen krankheiten, die von pathologischen reaktionen der spezifischen t-zellen abstammen.
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
IL95125A (en) * 1989-07-19 1995-07-31 Vandenbark Arthur Allen T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
CA2068888A1 (en) * 1989-11-15 1991-05-16 Brian L. Kotzin Method for measuring t-cell surface antigens in humans
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
CA2116526A1 (en) * 1991-08-28 1993-03-18 William V. Williams T cell receptor-based therapy for rheumatoid arthritis
US5747036A (en) * 1991-08-28 1998-05-05 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
JPH08501554A (ja) * 1992-09-14 1996-02-20 ブリガム・アンド・ウイメンズ・ホスピタル 慢性関節リウマチの治療剤および治療方法
EP1176981B1 (en) 1999-05-07 2005-11-30 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
EP1299128A2 (en) 2000-06-20 2003-04-09 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
AU2002237972B2 (en) 2001-01-31 2007-11-29 Biogen Idec Inc. Use of CD23 antagonists for the treatment of neoplastic disorders
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
RS20100366A (sr) 2002-12-16 2011-04-30 Genentech, Inc. Varijante imunoglobulina i njihova upotreba
KR101092171B1 (ko) 2003-04-09 2011-12-13 제넨테크, 인크. Ｔｎｆ-알파 저해제에 대해 부적절한 반응을 하는환자에서의 자가면역 질환의 치료법
BRPI0510915A (pt) 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
PL1853718T3 (pl) 2005-02-15 2016-01-29 Univ Duke Przeciwciała anty-CD19 i zastosowania w onkologii
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
AU2006223498A1 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
KR20100017514A (ko) 2007-05-07 2010-02-16 메디뮨 엘엘씨 항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
US8551493B2 (en) 2007-08-15 2013-10-08 Circassia Limited Peptide with reduced dimer formation
US9233107B2 (en) 2007-09-14 2016-01-12 Biogen Ma Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML)
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
WO2009140684A2 (en) 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
CA2739663A1 (en) 2008-10-10 2010-05-15 Anaphore, Inc. Polypeptides that bind trail-r1 and trail-r2
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
JP2013500993A (ja) 2009-07-31 2013-01-10 ジェネンテック， インコーポレイテッド Ｂｖ８アンタゴニスト又はｇ−ｃｓｆアンタゴニストを用いた腫瘍転移の阻害
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
MX2012002909A (es) 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
BR112012027001A2 (pt) 2010-04-23 2016-07-19 Genentech Inc produção de proteínas heteromultiméricas
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
KR20220070586A (ko) 2010-11-08 2022-05-31 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
RU2013140685A (ru) 2011-02-04 2015-03-10 Дженентек, Инк. ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
AU2012236304C1 (en) 2011-03-31 2017-01-05 Genentech, Inc. Methods of administering beta7 integrin antagonists
EP3653218B1 (en) 2011-07-04 2024-12-18 Mesoblast, Inc. Treating or preventing rheumatic disease
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
KR20140068877A (ko) 2011-08-17 2014-06-09 제넨테크, 인크. 불응성 종양에서의 혈관신생의 억제
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
EP3311847A1 (en) 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
JP6203838B2 (ja) 2012-06-27 2017-09-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
CA2884368C (en) 2012-10-05 2022-01-18 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
RU2015140573A (ru) 2013-02-25 2017-03-30 Дженентек, Инк. Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
WO2014151517A1 (en) 2013-03-15 2014-09-25 Intermune, Inc. Methods of improving microvascular integrity
AU2014241552B2 (en) 2013-03-27 2018-08-16 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
CA2939246A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
KR20250165670A (ko) 2014-05-06 2025-11-26 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
SG11201701627PA (en) 2014-09-12 2017-03-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
PL3227336T3 (pl) 2014-12-05 2019-11-29 Hoffmann La Roche Przeciwciała anty-CD79b i sposoby stosowania
MX2017010336A (es) 2015-02-26 2017-12-20 Genentech Inc Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
CN120665195A (zh) 2015-06-24 2025-09-19 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体
CN108473573A (zh) 2015-06-29 2018-08-31 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于器官移植中
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
AU2016333512B2 (en) 2015-10-02 2022-11-17 F. Hoffmann-La Roche Ag Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
KR20180075537A (ko) 2015-10-06 2018-07-04 제넨테크, 인크. 다발성 경화증을 치료하기 위한 방법
ES3038408T3 (en) 2015-12-30 2025-10-13 Hoffmann La Roche Formulations with reduced degradation of polysorbate
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN110402097A (zh) 2016-12-07 2019-11-01 普罗根尼蒂公司 胃肠道检测方法、装置和系统
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
AU2017378406A1 (en) 2016-12-14 2019-06-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
WO2018112232A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
CN118873822A (zh) 2016-12-14 2024-11-01 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病
EP3554345A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
KR20190097107A (ko) 2016-12-14 2019-08-20 프로제너티, 인크. Jak 저해제로의 위장관 질환의 치료 및 장치
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
US20210401895A1 (en) 2017-03-30 2021-12-30 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
EP3600414A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
WO2019040680A1 (en) 2017-08-23 2019-02-28 Krzar Life Sciences IMMUNOPROTEASOME INHIBITORS AND IMMUNOSUPPRESSANT AGENT IN THE TREATMENT OF AUTOIMMUNE DISORDERS
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20220364171A1 (en) 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
TW202330613A (zh) 2021-11-12 2023-08-01 美商建南德克公司 使用整聯蛋白β７拮抗劑治療克隆氏病之方法
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
AU2023393382A1 (en) 2022-12-14 2025-06-19 Pheon Therapeutics Ltd Cytotoxic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
WO1987003600A1 (en) * 1985-12-03 1987-06-18 T Cell Sciences, Inc. Cell-free t cell antigen receptor and its clinical utilities
US5340921A (en) * 1986-07-03 1994-08-23 T Cell Sciences, Inc. Γ, δT cell receptor and methods and detection

Also Published As

Publication number Publication date
JPH11196871A (ja) 1999-07-27
GR3024532T3 (en) 1997-12-31
EP0340109B1 (en) 1997-05-28
EP0340109A2 (en) 1989-11-02
FI891226A7 (fi) 1989-10-29
JPH0272197A (ja) 1990-03-12
AU3322089A (en) 1989-11-02
DE68928069T2 (de) 1997-11-13
DK203489A (da) 1989-10-29
NO891705D0 (no) 1989-04-25
ATE153704T1 (de) 1997-06-15
NO891705L (no) 1989-10-30
DE68928069D1 (de) 1997-07-03
DK203489D0 (da) 1989-04-27
IL89865A (en) 1994-12-29
FI891226A0 (fi) 1989-03-15
IL89865A0 (en) 1989-12-15
EP0340109A3 (en) 1991-10-23
HK1005597A1 (en) 1999-01-15
ES2104565T3 (es) 1997-10-16
AU635202B2 (en) 1993-03-18

Similar Documents

Publication Publication Date Title
FI891226L (fi) Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
FI891434L (fi) Framstaellning av vattenhaltiga polymeremulsioner i naervaro av hydrofobt modifierad hydroxietylcellulosa.
FI890577L (fi) Anordning foer kontinuerlig matning av haorfaerg i haor.
FI892088A0 (fi) Ultraljudsond foer proevning av u-roer i en vaermevaexlare.
FI890349L (fi) I reaktorn utfoerd stabilisering av polyolefiner medelst belagda stabilisatorer.
FI890233L (fi) Foerfarande foer reducering av faellningar i anlaeggningar foer indunstning av sulfitavlut.
FI881593L (fi) Kretsarrangemang foer kompensering av temperaturdriften i en fasdetektor.
FI884573A0 (fi) Foerfarande foer styrning av luftproduktionen i en skruvkompressor.
FI891094A0 (fi) Foerfarande foer behandling av avfallsvatten i undertryck.
FI891961L (fi) Anvaendning av icke-ioniska cellulosaetrar i taetnings- och bestrykningsmassor foer fogar.
FI890162L (fi) Foerfarande foer inaktivering av foeroekningsdugliga filtrerbara sjukdomsalstrare i blodplasmaprodukter.
FI890729A7 (fi) Anordning foer montering av delarna i en vinkelremledning.
FI891011L (fi) Foerfarande foer katalytisk oxidering av alkaner i alkohol- och ketonblandningar.
FI880137A7 (fi) Anlaeggning i valsverket av en superkalander.
FI885491A0 (fi) Anordning foer installering av vatten- och vaermeledningsroer i en byggnad.
FI881812A0 (fi) Foerfarande foer regenerering av betningssyror i zinkgalvaniseringsprocesser.
FI885615A0 (fi) Anordning foer raettande maetningsfel orsakat av aendring av provvolym i vaetskescintillationsraeknare.
FI884263A0 (fi) Anordning foer skaerpning av knivarna i en kapningsvals i en cellulosatorkmaskins arkskaermaskin.
FI880759A0 (fi) Anordning foer neddoppning av foeremaol i vaetska.
FI884744A0 (fi) Foerfarande foer bindande av i en kolpulverpanna uppstaoende svavelfoereningar.
FI881625A0 (fi) Foerfarande foer maetning av enstaka ojaemnheter i vaegen.
FI884254A7 (fi) Anordning foer upplysning av trappuppgaongar i hoeghus.
FI883716A7 (fi) Anordning foer foerflyttning i sidled av rullen i en foerflyttningsanordning.
FI883193A0 (fi) Anordning foer rengoering av luftmunstycken i sodapanna.
FI882237A0 (fi) Paosbildningsmaskin foer automatisk foerpackning av en livsmedelsprodukt i plastfoerpackning.

Legal Events

Date Code Title Description
FD Application lapsed
MM Patent lapsed

Owner name: THE BOARD OF TRUSTEES OF THE LELAND